PD-1 inhibitors work by blocking the PD-1 (programmed death-1) receptor on T cells, preventing cancer cells from evading the immune system and restoring the body's ability to fight cancer. Combining ...

Indaptus advanced its Decoy20 trial to test a combination with tislelizumab, aiming to enhance checkpoint inhibitor effectiveness in cancer treatment.

It’s not easy being Angel Reese. The rising WNBA star has reached another stratosphere of social media fame, and notoriety. Just this year alone, Reese has graced the cover of Vogue Magazine and ...

Bitcoin surged more than 20% from last week's lows on Monday and several other cryptocurrencies also rallied sharply after U.S. President Donald Trump raised the possibility of a new U.S ...

Presented promising PK, pharmacodynamic, and safety results for Decoy20 at the American Society for Clinical Oncology (ASCO) and the Society for Immunotherapy of Cancer (SITC) annual meetings.

Forget diamonds — a futuristic new digital ring could become the real marker of a committed relationship. The high-tech jewelry is being pitched as a way to help you emotionally connect with ...

One candidate, Decoy20, is currently in a Phase 1 clinical trial in the U.S. for patients with advanced cancers. The company’s technology aims to activate both innate and adaptive immune cells and ...

combination-mediated tumor eradication in multiple pre-clinical cancer models and one candidate (Decoy20) is currently being evaluated in a Phase 1 clinical trial in the U.S. for patients with ...